Drug or treatment

Ruxolitinib clinical trials

• 82Clinical trials
• 1New in 30 days
• 43Countries

Newest trials

All recruiting trials (82)

• Graft-versus-host disease after stem cell transplant: testing LBP-MARCO with ruxolitinib

  We are testing whether combining LBP-MARCO with ruxolitinib is safe for adults with GVHD after a stem cell transplant.

  Recruiting at 7 sites Phase 1 Memorial Sloan Kettering Cancer Center · Basking Ridge, New Jersey and 6 other locations · NCT07913672

• DMR-001 in CALR-mutant myeloproliferative neoplasms

  This study tests DMR-001 alone for CALR-mutant essential thrombocythemia or myelofibrosis, and in combination with ruxolitinib for CALR-mutant myelofibrosis.

  Recruiting at 3 sites Phase 1 Damora Therapeutics · Birmingham, Alabama and 35 other locations · NCT07849231

• Testing WJ01024 Alone and with Ruxolitinib for Myelofibrosis with Splenomegaly

  This early-phase study tests whether WJ01024, by itself or with ruxolitinib, is safe and tolerable and whether it shows signs of activity in adults with myelofibrosis and enlarged spleen.

  Recruiting Phase 1 Henan Cancer Hospital · Zhengzhou, Henan · NCT07802405

• Belumosudil vs. Ruxolitinib for hepatic cGVHD after HSCT

  This trial tests whether belumosudil or ruxolitinib works better for hepatic chronic GVHD after a stem cell transplant in people 12 and older.

  Recruiting First Affiliated Hospital of Zhejiang University · Hangzhou, Zhejiang · NCT07794514

• Topical ruxolitinib for adults with pyoderma gangrenosum

  This pilot study tests a topical cream of ruxolitinib to see if it helps heal PG ulcers in adults without adding systemic immunosuppressants.

  Recruiting Phase 2 Oregon Health and Science University · Portland, Oregon · NCT07783412

• Ruxolitinib Cream Plus Corticosteroids for Facial Non-Segmental Vitiligo in Real-World Practice

  This real-world study tests whether adding 1.5% ruxolitinib cream to corticosteroids helps people 12 and older with active facial non-segmental vitiligo.

  Recruiting at 6 sites Dermavon Holdings Limited · Shenzhen, Guangdong and 19 other locations · NCT07673640

• Elritercept vs. placebo for adults with myelofibrosis and anemia on ruxolitinib

  This study tests whether elritercept can improve anemia in adults with myelofibrosis who are taking ruxolitinib, compared with placebo.

  Recruiting at 11 sites Phase 3 Takeda · Gilbert, Arizona and 213 other locations · NCT07623161

• Ruxolitinib for Graft-Versus-Host Disease in Clinical Practice

  This study tests how well Jakavi (ruxolitinib) works and how safe it is for people with acute or chronic GVHD being treated in real-world medical settings.

  Recruiting Novartis · Tokyo · NCT07594587

• Ruxolitinib with azacitidine maintenance after reduced-intensity stem cell transplant for AML

  This study tests different doses of ruxolitinib first alone, then with azacitidine maintenance, in adults with acute myeloid leukemia undergoing reduced-intensity allogeneic stem cell transplantation to see if it is safe and tolerable and may help prevent relapse.

  Recruiting Phase 1 OHSU Knight Cancer Institute · Portland, Oregon · NCT07548983

• Ropeginterferon add-on to ruxolitinib in myelofibrosis

  This trial tests whether adding ropeginterferon alfa-2b to ongoing ruxolitinib treatment is safe and helpful for adults with myelofibrosis.

  Recruiting Phase 1 University of Utah · Salt Lake City, Utah · NCT07521046

• CART123 Cells With or Without Ruxolitinib for Relapsed/Refractory AML

  This trial tests CART123 cells alone or with ruxolitinib to see if they help kids and young adults with relapsed or treatment‑resistant AML.

  Recruiting Phase 1 Children's Hospital of Philadelphia · Philadelphia, Pennsylvania · NCT07464951

• Ruxolitinib for IEC-HS after CAR-T therapy

  This pilot study tests whether ruxolitinib can help treat IEC-HS that can occur after CAR-T therapy in adults.

  Recruiting Phase 1 Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins · Baltimore, Maryland · NCT07424222

• Ruxolitinib to prevent graft-versus-host disease after allogeneic stem cell transplant

  This trial will test whether adding ruxolitinib to standard drugs better prevents chronic graft-versus-host disease in adults receiving an allogeneic stem cell transplant for blood cancers.

  Recruiting at 7 sites Phase 2 Memorial Sloan Kettering Cancer Center · Basking Ridge, New Jersey and 6 other locations · NCT07359859

• Pelabresib plus ruxolitinib for adults with myelofibrosis

  This trial will see if adding pelabresib to ruxolitinib helps adults with primary myelofibrosis or post‑PV/post‑ET myelofibrosis who have not previously taken JAK inhibitor therapy.

  Recruiting at 165 sites Phase 3 Novartis · Denver, Colorado and 164 other locations · NCT07357727

• Ruxolitinib maintenance after stem cell transplant for T‑cell lymphoma

  This phase II trial tests whether taking ruxolitinib after a stem cell transplant can lower the chance of relapse and graft‑versus‑host disease for people treated for T‑cell lymphoma.

  Recruiting at 2 sites Phase 2 Ohio State University Comprehensive Cancer Center · Columbus, Ohio and 1 other locations · NCT07356245

• Combination therapy with ruxolitinib, cladribine, and venetoclax in relapsed/refractory T-cell prolymphocytic leukemia

  This study tests whether a three-drug combo can control relapsed or refractory T-PLL in adults.

  Recruiting Phase 1/2 M.D. Anderson Cancer Center · Houston, Texas · NCT07311746

• Ruxolitinib with CHOP for untreated nodal TFH cell lymphoma

  This phase 1 trial tests whether adding ruxolitinib to CHOP chemotherapy is safe and tolerable in adults with untreated nodal TFH cell lymphoma.

  Recruiting Phase 1 City of Hope Medical Center · Duarte, California · NCT07278856

• Ruxolitinib-enhanced haploidentical transplant for children and young adults with sickle cell disease

  This trial will test whether adding ruxolitinib to a reduced-intensity haploidentical transplant lowers the risk of graft failure in children and young adults with sickle cell disease.

  Recruiting Phase 1/2 Arkansas Children's Hospital Research Institute · Aurora, Colorado and 3 other locations · NCT07252050

• Low-dose post-transplant cyclophosphamide plus tacrolimus and ruxolitinib to prevent GVHD after myeloablative peripheral blood stem cell transplant

  This test sees if adding low-dose post-transplant cyclophosphamide with tacrolimus and ruxolitinib can reduce severe acute graft-versus-host disease in adults receiving myeloablative peripheral blood stem cell transplants for leukemia or myelodysplasia.

  Recruiting at 3 sites Phase 2 Ohio State University Comprehensive Cancer Center · Birmingham, Alabama and 2 other locations · NCT07249346

• Ruxolitinib given before, during, and after donor stem cell transplant for older adults with myelofibrosis or MDS/MPN overlap

  This phase II test tries whether giving ruxolitinib before, during, and after an allogeneic stem cell transplant helps older adults with myelofibrosis or MDS/MPN overlap have better transplant outcomes and fewer complications like graft-versus-host disease.

  Recruiting Phase 2 Fred Hutchinson Cancer Center · Seattle, Washington · NCT07228624

• Retifanlimab plus ruxolitinib for advanced kidney and lung cancers

  This trial will test whether taking ruxolitinib twice daily together with retifanlimab infusions every 4 weeks is safe and can help people with metastatic renal cell carcinoma or non-small cell lung cancer who progressed on prior PD-1/PD-L1 therapy.

  Recruiting Phase 1/2 University of California, San Diego · La Jolla, California · NCT07219576

• Adding etanercept to ruxolitinib for severe steroid-refractory acute GVHD

  This trial will test whether adding the TNF blocker etanercept to ruxolitinib helps people with severe acute GVHD that did not respond to steroids.

  Recruiting First Affiliated Hospital of Zhejiang University · Hangzhou, Zhejiang · NCT07184853

• Factors influencing how well ruxolitinib cream works in vitiligo

  This study tests whether patient and disease characteristics affect how well ruxolitinib 1.5% cream works for people aged 12 and older with non‑segmental vitiligo covering under 10% of the body.

  Recruiting Peking University Third Hospital · Beijing · NCT07153666

• Axatilimab plus ruxolitinib for people with myelofibrosis or CMML

  This trial tests whether adding axatilimab, an antibody that targets CSF1R, to ruxolitinib can help control disease and symptoms in adults with myelofibrosis or chronic myelomonocytic leukemia (CMML).

  Recruiting Phase 1/2 M.D. Anderson Cancer Center · Houston, Texas · NCT07128381

• Ruxolitinib plus decitabine intensified conditioning for AML patients having allogeneic stem cell transplant

  This trial will see if adding ruxolitinib and decitabine to standard busulfan-based conditioning before allogeneic HSCT lowers relapse in high‑risk AML patients in first complete remission (CR1).

  Recruiting Phase 4 Chinese PLA General Hospital · Beijing, Beijing Municipality · NCT07101588

• Ruxolitinib for adults with previously treated idiopathic multicentric Castleman disease

  This trial will try ruxolitinib (Jakafi) in adults with iMCD who did not improve with or cannot take siltuximab or tocilizumab.

  Recruiting Phase 2 University of Pennsylvania · Philadelphia, Pennsylvania · NCT07085039

• Maximal-use ruxolitinib cream for adults and teens with hidradenitis suppurativa

  This trial will test whether applying ruxolitinib cream over large skin areas is safe and tolerable in adults and adolescents with hidradenitis suppurativa.

  Recruiting at 16 sites Phase 1 Incyte Corporation · Phoenix, Arizona and 20 other locations · NCT07049575

• Biomarker-guided ruxolitinib to prevent chronic graft-versus-host disease after allogeneic stem cell transplant

  This study tests whether giving ruxolitinib based on blood GVHD biomarkers around day 100 after an allogeneic stem cell transplant can prevent chronic GVHD in adults at higher biomarker risk.

  Recruiting Phase 1 City of Hope Medical Center · Duarte, California · NCT07025538

• Adding ruxolitinib to standard radiation and temozolomide for newly diagnosed glioblastoma

  This trial will try whether adding the oral drug ruxolitinib to standard radiation and temozolomide helps adults newly diagnosed with glioblastoma.

  Recruiting at 2 sites Phase 2 Baptist Health South Florida · Miami, Florida and 1 other locations · NCT06991101

• Compare two post-transplant drug combinations to prevent graft-versus-host disease

  This phase 2 trial will test whether giving ruxolitinib instead of mycophenolate mofetil, together with cyclophosphamide and sirolimus after a stem cell transplant, better prevents graft-versus-host disease in older adults with AML or related blood cancers.

  Recruiting Phase 2 M.D. Anderson Cancer Center · Houston, Texas · NCT06973668

• Ruxolitinib treatment for acute graft-versus-host disease

  This study is testing if ruxolitinib can help people with acute graft-versus-host disease who haven't improved with regular steroid treatments.

  Recruiting at 10 sites Phase 2 Icahn School of Medicine at Mount Sinai · Duarte, California and 13 other locations · NCT06936566

• Combining Roginolisib with Ruxolitinib for Myelofibrosis Patients Not Responding to JAK Inhibitors

  This study is testing if combining two medications, roginolisib and ruxolitinib, can help adults with myelofibrosis who haven't responded well to other treatments.

  Recruiting at 11 sites Phase 1/2 iOnctura · Florence, Florence and 11 other locations · NCT06887803

• Topical ruxolitinib cream to treat stubborn skin symptoms of dermatomyositis

  This will test whether applying 1.5% ruxolitinib cream helps adults with dermatomyositis whose skin symptoms have not improved with other treatments.

  Recruiting Phase 2 The Cleveland Clinic · Cleveland, Ohio · NCT06857240

• Ruxolitinib for corticosteroid-refractory chronic graft-versus-host disease in Chinese patients

  This trial will try ruxolitinib in Chinese adolescents (12+) and adults whose chronic graft-versus-host disease has not improved with corticosteroids.

  Recruiting at 22 sites Phase 4 Novartis · Hefei, Anhui and 21 other locations · NCT06824103

• Ruxolitinib cream for children 6 to under 12 with nonsegmental vitiligo

  This will test whether ruxolitinib cream can safely produce skin repigmentation in children aged 6 to under 12 with nonsegmental vitiligo.

  Recruiting at 78 sites Phase 3 Incyte Corporation · Buenos Aires and 77 other locations · NCT06804811

• Combining ruxolitinib and ulixertinib for treating myelofibrosis

  This study is testing if combining two medications, ruxolitinib and ulixertinib, can help people with myelofibrosis who haven't had enough relief from ruxolitinib alone.

  Recruiting at 8 sites Phase 1/2 Memorial Sloan Kettering Cancer Center · Boston, Massachusetts and 8 other locations · NCT06773195

• Ropeginterferon alfa-2b added to ruxolitinib for people with myelofibrosis

  This will try adding ropeginterferon alfa-2b to ongoing ruxolitinib for adults with myelofibrosis who have had a suboptimal response to ruxolitinib alone.

  Recruiting Phase 2 The University of Hong Kong · Hong Kong · NCT06770842

• Preventing GVHD in children and young adults with blood cancers

  This study is testing a new treatment plan to see if it can help prevent graft-versus-host disease in children and young adults with blood cancers after they receive a transplant.

  Recruiting Phase 2/3 Federal Research Institute of Pediatric Hematology, Oncology and Immunology · Moscow · NCT06756152

• Comparing Ruxolitinib with Steroids for Chronic Graft-versus-Host Disease Treatment

  This study is testing if a new treatment combining Ruxolitinib with steroids can help people with moderate to severe chronic graft-versus-host disease feel better compared to just using steroids alone.

  Recruiting Phase 2 Seoul St. Mary's Hospital · Seoul, Banpo-daero/Seocho-gu · NCT06756061

• Topical Ruxolitinib for treating vitiligo in adults

  This study is testing if a new cream called Ruxolitinib can help adults with vitiligo on their face and neck feel better when other treatments haven't worked.

  Recruiting Phase 2/3 Hospital Authority, Hong Kong · Hong Kong · NCT06719024

• Comparing Ruxolitinib and Prednisone for treating chronic GVHD

  This study is testing whether Ruxolitinib works better than Prednisone for adults with chronic graft-versus-host disease who need treatment.

  Recruiting at 6 sites Phase 2 H. Lee Moffitt Cancer Center and Research Institute · Miami, Florida and 5 other locations · NCT06660355

• Examining the effects of ruxolitinib cream versus topical corticosteroids in pregnant women with atopic dermatitis

  This study is testing whether using ruxolitinib cream during pregnancy is safer for babies than using regular steroid creams in women with atopic dermatitis.

  Recruiting Incyte Corporation · Morrisville, North Carolina · NCT06627335

• Combining ruxolitinib and enzalutamide for advanced prostate cancer treatment

  This study is testing if combining two medications, ruxolitinib and enzalutamide, can safely help men with advanced prostate cancer that hasn't responded to hormone therapy.

  Recruiting Phase 1/2 University of Michigan Rogel Cancer Center · Chicago, Illinois and 2 other locations · NCT06616155

• Comparing two treatment regimens for Graft-versus-host Disease after stem cell transplantation

  This study is testing two different treatment plans for adults with Graft-versus-host Disease after stem cell transplantation to see which one works better, especially for those who haven't responded to steroids.

  Recruiting at 30 sites Phase 3 Incyte Corporation · Palo Alto, California and 29 other locations · NCT06615050

• Evaluating Ruxolitinib Cream for Children with Nonsegmental Vitiligo

  This study is testing if ruxolitinib cream can help children with nonsegmental vitiligo regain skin color better than a regular cream.

  Recruiting at 83 sites Phase 3 Incyte Corporation · Birmingham, Alabama and 97 other locations · NCT06548360

• Ruxolitinib for people with inclusion body myositis

  This trial will test whether ruxolitinib can help improve walking distance, muscle strength, and breathing in adults 45 and older with inclusion body myositis.

  Recruiting at 10 sites Phase 2 Assistance Publique - Hôpitaux de Paris · Angers, France and 20 other locations · NCT06536166

• Observational study on ruxolitinib for myelofibrosis patients

  This study looks at how well ruxolitinib works for people with myelofibrosis and how different factors affect their long-term survival.

  Recruiting at 26 sites IRCCS Azienda Ospedaliero-Universitaria di Bologna · Cosenza, Calabria and 25 other locations · NCT06516406

• Adding navtemadlin to ruxolitinib for myelofibrosis patients with poor response

  This study is testing if adding a new drug called navtemadlin to ruxolitinib can help myelofibrosis patients who aren't doing well on ruxolitinib alone.

  Recruiting at 214 sites Phase 3 Kartos Therapeutics, Inc. · Birmingham, Alabama and 214 other locations · NCT06479135

• Comparing two conditioning regimens for haploidentical stem cell transplantation

  This study is testing two different treatment plans for patients getting stem cell transplants from partially matched donors to see which one works better in preventing complications like graft failure and relapse.

  Recruiting Phase 2 St. Petersburg State Pavlov Medical University · Saint Petersburg · NCT06477549

• Using high doses of ruxolitinib and stem cell transplant for myelofibrosis patients with enlarged spleens

  This study is testing if giving high doses of ruxolitinib and busulfan before a stem cell transplant can help people with myelofibrosis and enlarged spleens live longer and have better recovery after the transplant.

  Recruiting Phase 2 M.D. Anderson Cancer Center · Houston, Texas · NCT06345495

• Combining Ivosidenib and Ruxolitinib for Advanced Myeloproliferative Neoplasms with IDH1 Mutation

  This study is testing if combining two medications, ivosidenib and ruxolitinib, can help people with advanced myeloproliferative neoplasms that have an IDH1 mutation feel better and improve their treatment outcomes.

  Recruiting at 2 sites Phase 1 University of Chicago · Chicago, Illinois and 1 other locations · NCT06291987

• Evaluating Ruxolitinib Cream for Discoid Lupus Erythematosus

  This study is testing if a new cream can help adults with discoid lupus erythematosus reduce their skin lesions and improve their condition.

  Recruiting at 2 sites Phase 2 Innovaderm Research Inc. · Fredericton, New Brunswick and 1 other locations · NCT06261021

• Comparing outcomes for pregnant women with atopic dermatitis using ruxolitinib cream

  This study is trying to see if using ruxolitinib cream during pregnancy is safe for women with mild to moderate atopic dermatitis and their babies compared to those who don’t use it.

  Recruiting Incyte Corporation · Morrisville, North Carolina · NCT06259669

• Ruxolitinib plus fostamatinib for adults with steroid-refractory chronic graft-versus-host disease

  This tests whether adding fostamatinib to ruxolitinib helps adults with chronic GvHD who haven't responded well to steroids.

  Recruiting Phase 1 Duke University · Durham, North Carolina · NCT06233110

• Combination treatment for relapsed or refractory multiple myeloma

  This study is testing a new combination of lower-dose Selinexor, Ruxolitinib, and methylprednisolone to see if it can help people with relapsed or refractory multiple myeloma who have few treatment options left.

  Recruiting Phase 1 Oncotherapeutics · West Hollywood, California · NCT06225310

• Using serum BCMA levels to track disease progression in multiple myeloma

  This study is testing if measuring BCMA levels in the blood can help track how well new treatments work for people with progressive multiple myeloma.

  Recruiting Early Phase 1 Oncotherapeutics · West Hollywood, California · NCT06209606

• Using PTCy and Ruxolitinib to prevent GVHD after stem cell transplants in children with immune disorders

  This study is testing if a new combination of medications can help prevent graft-versus-host disease in children with immune disorders who are getting stem cell transplants.

  Recruiting Phase 2 Federal Research Institute of Pediatric Hematology, Oncology and Immunology · Moscow · NCT06199427

• Using ruxolitinib with a modified HLH-94 regimen to treat hemophagocytic lymphohistiocytosis.

  This study is testing if a new combination of ruxolitinib and a modified treatment plan can help adults newly diagnosed with hemophagocytic lymphohistiocytosis feel better and live longer.

  Recruiting at 4 sites Phase 2 University of California, San Francisco · Irvine, California and 3 other locations · NCT06160791

• Using ruxolitinib, tacrolimus, and methotrexate to prevent graft versus host disease in young patients after bone marrow transplant

  This study is testing if a combination of three medications can help prevent graft versus host disease in young patients after they receive a bone marrow transplant for certain types of leukemia or blood disorders.

  Recruiting Phase 2 City of Hope Medical Center · Duarte, California · NCT06128070

• Evaluating INCA033989 for treating myeloproliferative neoplasms

  This study is testing a new treatment called INCA033989, alone and with another drug, to see if it’s safe and effective for people with myeloproliferative neoplasms who have certain mutations.

  Recruiting at 13 sites Phase 1 Incyte Corporation · Duarte, California and 12 other locations · NCT06034002

• Using Ruxolitinib to prevent complications after haploidentical stem cell transplants

  This study is testing if the drug Ruxolitinib can help prevent complications like graft-versus-host disease in patients receiving stem cell transplants from partially matched donors.

  Recruiting Phase 1 Washington University School of Medicine · St Louis, Missouri · NCT06008808

• Combining neratinib and ruxolitinib for treating metastatic triple-negative breast cancer

  This study is testing if combining two medications, neratinib and ruxolitinib, can help people with advanced triple-negative breast cancer who have already been treated with chemotherapy.

  Recruiting Early Phase 1 Baylor Research Institute · Dallas, Texas · NCT06008275

• Combining pegylated interferon α-2b with ruxolitinib for treating resistant polycythemia vera

  This study is testing if combining two medications, pegylated interferon α-2b and ruxolitinib, can help people with polycythemia vera who haven't responded well to other treatments feel better.

  Recruiting Phase 2 Institute of Hematology & Blood Diseases Hospital, China · Tianjin · NCT05870475

• Combining Azacitidine and Ruxolitinib for treating higher-risk MDS/MPN

  This study is testing if combining two medications, Azacitidine and Ruxolitinib, can help people with higher-risk Myelodysplastic Syndromes or Myeloproliferative Neoplasms feel better and improve their health.

  Recruiting Phase 2 The First Affiliated Hospital with Nanjing Medical University · Nanjing, Jiangsu · NCT05817955

• Ruxolitinib as first-line treatment for primary haemophagocytic lymphohistiocytosis

  This will test whether ruxolitinib plus corticosteroids helps children and young adults with primary HLH survive until they can receive a stem cell transplant.

  Recruiting Phase 2 Assistance Publique - Hôpitaux de Paris · Paris, Île-de-France Region · NCT05762640

• Ruxolitinib and venetoclax added to chemotherapy for children and young adults with relapsed or refractory ALL/LBL

  This trial tests whether adding ruxolitinib and venetoclax to dexamethasone, cyclophosphamide and cytarabine helps children and young adults with relapsed or refractory acute lymphoblastic leukemia or lymphoblastic lymphoma who have IL7R/JAK-STAT pathway changes.

  Recruiting at 3 sites Phase 1/2 Princess Maxima Center for Pediatric Oncology · Vienna and 32 other locations · NCT05745714

• Combining ruxolitinib and abemaciclib for treating myelofibrosis

  This study is testing if combining two medications, ruxolitinib and abemaciclib, can help people with myelofibrosis who haven't responded well to ruxolitinib alone.

  Recruiting at 7 sites Phase 1 Memorial Sloan Kettering Cancer Center · Basking Ridge, New Jersey and 6 other locations · NCT05714072

• Using ruxolitinib to treat T-cell large granular lymphocytic leukemia

  This study is testing if the medication ruxolitinib can help shrink tumors in people with T-cell large granular lymphocytic leukemia and improve their quality of life.

  Recruiting at 3 sites Phase 2 Ohio State University Comprehensive Cancer Center · Boston, Massachusetts and 2 other locations · NCT05592015

• New treatment for myelofibrosis using CK0804 with ruxolitinib

  This study is testing a new treatment called CK0804 for people with myelofibrosis who haven't felt better on ruxolitinib to see if it can help them more.

  Recruiting at 3 sites Phase 1 Cellenkos, Inc. · Sacramento, California and 3 other locations · NCT05423691

• Evaluating Ruxolitinib for Hair Regrowth in APECED-Associated Alopecia Areata

  This study is testing if a medication called ruxolitinib can help people aged 12 to 65 with a rare autoimmune condition and severe hair loss to regrow their hair and improve other symptoms.

  Recruiting Phase 2 National Institutes of Health Clinical Center (CC) · Bethesda, Maryland · NCT05398809

• Combining TL-895 with Ruxolitinib for treating Myelofibrosis

  This study is testing if combining TL-895 with Ruxolitinib can help people with Myelofibrosis feel better, especially those who haven't responded well to Ruxolitinib alone.

  Recruiting at 19 sites Phase 1/2 Telios Pharma, Inc. · Birmingham, Alabama and 18 other locations · NCT05280509

• Ruxolitinib and chidamide–intensified busulfan/cyclophosphamide conditioning for peripheral blood stem cell transplant

  This trial tests whether adding ruxolitinib and chidamide to a busulfan/cyclophosphamide conditioning regimen helps people aged 12–65 with high‑risk B‑cell acute lymphoblastic leukemia who are receiving allogeneic peripheral blood stem cell transplants.

  Recruiting Phase 2 Chinese PLA General Hospital · Beijing, Beijing Municipality · NCT05088226

• Evaluating KER-050 for treating Myelofibrosis

  This study is testing a new treatment called KER-050 to see if it can help people with Myelofibrosis improve their blood cell counts and overall quality of life, both on its own and with another medication.

  Recruiting at 39 sites Phase 2 Takeda · Concord, New South Wales and 45 other locations · NCT05037760

• Using cord blood cells with ruxolitinib to treat steroid-refractory acute graft versus host disease

  This study is testing whether adding special cells from cord blood to the medication ruxolitinib can help people with acute graft versus host disease who haven't responded to steroids.

  Recruiting Early Phase 1 M.D. Anderson Cancer Center · Houston, Texas · NCT04744116

• Using Ruxolitinib to treat symptoms of essential thrombocythemia and polycythemia vera

  This study is testing if the drug Ruxolitinib can help reduce symptoms for people with low-risk essential thrombocythemia and polycythemia vera.

  Recruiting at 3 sites Phase 2 Massachusetts General Hospital · Boston, Massachusetts and 3 other locations · NCT04644211

• Combining decitabine with ruxolitinib, fedratinib, or pacritinib for treating advanced myeloproliferative neoplasms

  This study is testing if combining decitabine with other medications can help patients with advanced blood cancers get ready for a stem cell transplant.

  Recruiting Phase 2 University of Washington · Seattle, Washington · NCT04282187

• Comparing Ruxolitinib to Hydroxycarbamide or Interferon for High Risk Polycythemia Vera

  This study is testing whether ruxolitinib works better than hydroxycarbamide or interferon for people with high-risk polycythemia vera.

  Recruiting at 53 sites Phase 3 University of Birmingham · Aberdeen and 54 other locations · NCT04116502

• Ruxolitinib plus venetoclax, with or without azacitidine, for relapsed or refractory AML

  This phase 1 trial tests whether adding ruxolitinib to venetoclax, with or without azacitidine, is safe and helps adults whose AML has returned or not responded to prior treatment.

  Recruiting at 3 sites Phase 1 OHSU Knight Cancer Institute · Columbus, Ohio and 2 other locations · NCT03874052

• Combining nivolumab and ruxolitinib for treating relapsed Hodgkin lymphoma

  This study is testing if combining two drugs, nivolumab and ruxolitinib, can safely help people with relapsed Hodgkin lymphoma feel better.

  Recruiting at 3 sites Phase 1/2 Big Ten Cancer Research Consortium · Chicago, Illinois and 5 other locations · NCT03681561

• Combining ruxolitinib with chemotherapy for young patients with Ph-like acute lymphoblastic leukemia

  This study is testing if adding a drug called ruxolitinib to standard chemotherapy can help young patients with a specific type of leukemia feel better and improve their treatment results.

  Recruiting Phase 1 University of Chicago · Chicago, Illinois and 1 other locations · NCT03571321

• Combining Ruxolitinib, Steroids, and Lenalidomide for Patients with Relapsed Multiple Myeloma

  This study is testing a new combination of ruxolitinib, steroids, and lenalidomide to see if it can help people with relapsed multiple myeloma feel better and improve their treatment results.

  Recruiting at 5 sites Phase 1 Oncotherapeutics · Alhambra, California and 12 other locations · NCT03110822

• Testing ruxolitinib for relapsed or refractory T or NK cell lymphoma

  This study is testing if the drug ruxolitinib can help people with T or NK cell lymphoma that hasn't responded to other treatments by shrinking their tumors and improving their health.

  Recruiting at 6 sites Phase 2 Memorial Sloan Kettering Cancer Center · Miami, Florida and 9 other locations · NCT02974647

Quick answers

How many clinical trials of Ruxolitinib are recruiting right now?

82, as of November 12, 2026. 1 of them was first registered in the last 30 days. We update this list each time we refresh our data from ClinicalTrials.gov.

Where are these trials running?

In 43 countries. The most sites are in United States (56 trials), China (11 trials), Italy (9 trials), France (9 trials), Spain (8 trials). Each study page lists its sites and which ones are recruiting.

What phases are they in?

Phase 2: 30, Phase 1: 20, Phase 1/2: 10, Phase 3: 7. Trials with no phase listed are usually device, behavioural or observational studies.

How do I join one?

Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.

Find the studies that fit you

A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.

Describe your situation →